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Abstract
Background
Combined fatty acid amide hydrolase (FAAH) and cyclooxygenase (COX) inhibition is a
promising approach for pain-relief. The Flu-AM1 and Ibu-AM5 derivatives of flurbiprofen
and ibuprofen retain similar COX-inhibitory properties and are more potent inhibitors of
FAAH than the parent compounds. However, little is known as to the nature of their interac-
tion with FAAH, or to the importance of their chirality. This has been explored here.
Methodology/Principal Findings
FAAH inhibitory activity was measured in rat brain homogenates and in lysates expressing
either wild-type or FAAHT488A-mutated enzyme. Molecular modelling was undertaken using
both docking and molecular dynamics. The (R)- and (S)-enantiomers of Flu-AM1 inhibited
rat FAAH with similar potencies (IC50 values of 0.74 and 0.99 μM, respectively), whereas
the (S)-enantiomer of Ibu-AM5 (IC50 0.59 μM) was more potent than the (R)-enantiomer
(IC50 5.7 μM). Multiple inhibition experiments indicated that both (R)-Flu-AM1 and (S)-Ibu-
AM5 inhibited FAAH in a manner mutually exclusive to carprofen. Computational studies
indicated that the binding site for the Flu-AM1 and Ibu-AM5 enantiomers was located
between the acyl chain binding channel and the membrane access channel, in a site over-
lapping the carprofen binding site, and showed a binding mode in line with that proposed for
carprofen and other non-covalent ligands. The potency of (R)-Flu-AM1 was lower towards
lysates expressing FAAHmutated at the proposed carprofen binding area than in lysates
expressing wild-type FAAH.
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Conclusions/Significance
The study provides kinetic and structural evidence that the enantiomers of Flu-AM1 and
Ibu-AM5 bind in the substrate channel of FAAH. This information will be useful in aiding the
design of novel dual-action FAAH: COX inhibitors.
Introduction
Fatty acid amide hydrolase (FAAH) is a hydrolytic enzyme belonging to the family of serine
hydrolases. It has a wide substrate specificity, capable of hydrolysing N-acylethanolamines and
N-acyltaurines. Structurally, the enzyme is a membrane-bound homodimer, whereby the sub-
strate accesses its catalytic active site via a membrane channel [1]. The catalysis of the most-
well studied substrate, the endogenous cannabinoid ligand anandamide (arachidonoylethano-
lamide, AEA) is brought about by the formation of an acyl-enzyme intermediate in association
with substrate binding to a triad of amino acids, Lys142, Ser217 and Ser241 [2,3]. Knowledge of
the structure of rat FAAH, and subsequent studies using humanised rat FAAH, have resulted
in a series of computational, mutagenesis and structural studies investigating the different clas-
ses of FAAH inhibitors with the enzyme (see e.g. [3–13]; for a review, see [14]).
In 1996, Paria et al. [15] reported that the non-steroidal anti-inflammatory drug (NSAID)
indomethacin reduced the ability of uterine microsomes to hydrolyse AEA following treatment
both ex vivo (100 μg/mouse s.c.) and in vitro (10 μM; [15]). The ability of indomethacin to
inhibit FAAH is shared by a number of other NSAIDs including ibuprofen [16], flurbiprofen
[17] and carprofen [18]. In an X-ray crystallography study of FAAH complexed with carpro-
fen, Bertolacci et al. [11] reported that this NSAID was able to bind to an area at the entrance
of the channel allowing the substrate access to the active site. In support of this model, the
authors showed further that the potency of carprofen was lower in mutant FAAHT488A (a key
residue in the interaction of carprofen with the enzyme) than in the wild-type FAAH [11].
Although the NSAIDs like ibuprofen, flurbiprofen and carprofen inhibit FAAH, their
potencies are modest (in the middle to high micromolar concentrations) at physiological pH
values. However, a number of structure-activity relationship studies have identified more
potent compounds [13,19–22]. Of these, the amide derivative of ibuprofen with 2-amino-
3-methylpyridine (Ibu-AM5) is particularly interesting, since it retains the cyclooxygenase-
inhibitory properties of the parent compound, and in vivo can alleviate visceral pain without
producing overt ulcerogenic effects [19,21,23], as can the combination of an NSAID with an
FAAH inhibitor [24]. The corresponding amide analogue of flurbiprofen (Flu-AM1) can also
inhibit FAAH in submicromolar concentrations and retains the cyclooxygenase (COX)-inhibi-
tory properties of the parent compound [22]. Most recently, a compound with elements of flur-
biprofen and a carbamate-based FAAH inhibitor, that inhibits both FAAH and COX and
which shows anti-inflammatory and gastroprotective properties, has been disclosed [25].
FAAH shows pronounced enantioselectivity towards inhibition by chiral irreversible phenyl
alkylcarbamates, azetidine urea inhibitors and slowly reversible 1,3,4-oxadiazol-2-one inhibi-
tors and by ibuprofen itself [8,9,13,17]. Both Ibu-AM5 and Flu-AM1 retain the chiral centre of
the parent profens, and in a recent study published in this Journal [26], we reported that the
two enantiomers of Flu-AM1 had similar potencies towards mouse brain FAAH. That paper
was primarily focussed upon the COX-inhibitory properties of the Flu-AM1 enantiomers
rather than upon FAAH, and the Ibu-AM5 enantiomers were not investigated. In the present
study, we have investigated in detail the interaction between the enantiomers of Ibu-AM5,
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Flu-AM1 and rat FAAH using biochemical, molecular biological, and molecular modelling
methodologies.
Materials and Methods
Ethics statement
Ethical permission for the animal experiments was obtained from the local animal research
ethical committee (Umeå Ethical Committee for Animal Research, Umeå, Sweden).
Compounds and materials
Radioactive arachidonoyl ethanolamide[1-3H] ([3H]-AEA) was obtained from American
Radiolabeled Chemicals, Inc (St Louis, MO, USA). (R)(-)-Ibuprofen and (S)(+)-ibuprofen,
were purchased from Santa Cruz Biotechnology Inc. (Dallas, Texas, USA). The enantiomers of
Flu-AM1 (structures, see Fig 1) were synthesised as described elsewhere [26]). AEA and
URB597 (cyclohexylcarbamic acid 30-carbamoylbiphenyl-3-yl ester) were purchased from Cay-
man Chemical Co. (Ann Arbor, MI, USA). Carprofen was obtained from Sigma-Aldrich Inc,
St. Louis, (MO, U.S.A.). Substrates were dissolved in ethanol or DMSO as appropriate.
Synthesis of the enantiomers of Ibu-AM5 and ibufenac-AM1
Enantiomerically pure (R)(-)-Ibu-AM5 and (S)(+)-Ibu-AM5 (see Fig 1) were synthesized using
a slight modification of the procedure previously described for the racemate [23]. Commercial
(R)(-)-ibuprofen and (S)(+)-ibuprofen were coupled with 2-amino-3-methylpyridine in the
presence of 1-(3-dimethylaminopropyl)-3-ethylcardodiimide hydrochloride (EDC) and hydro-
xybenzotriazole (HOBt) in acetonitrile solution.
Fig 1. Inhibition of FAAH by the enantiomers of Flu-AM1 and Ibu-AM5 and by Ibufenac-AM1. Structures of the compounds are shown in Panels A-C: A,
Flu-AM1; B, Ibu-AM5; C, ibufenac-AM1. The asterisks show the chiral centres. In Panels D-F, the inhibition of 0.5 μM [3H]AEA hydrolysis in rat brain
homogenates by the compounds is shown. Data are means ± SEM (when not enclosed by the symbols), N = 3 for the enantiomers of D, Flu-AM1; E, Ibu-AM5
and F, racemic Ibu-AM5 and Ibufenac-AM1.
doi:10.1371/journal.pone.0142711.g001
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Melting points were determined on a Stuart Scientific Melting point SMP1 and are uncor-
rected. 1H NMR spectra were recorded on a Varian Inova 500 spectrometer. The chemical
shifts (δ) are reported in part per million downfield from tetramethylsilane (TMS), which was
used as internal standard. Infrared spectra were recorded on a Bruker Vector 22 spectrometer
in Nujol mull. The main bands are given in cm-1. Positive-ion electrospray ionization (ESI)
mass spectra were recorded on a double-focusing Finnigan MAT 95 instrument with BE geom-
etry. All products reported showed 1H NMR spectra in agreement with the assigned structures.
The purity of tested compounds was determined by combustion elemental analyses conducted
by the Microanalytical Laboratory of the Chemistry Department of the University of Ferrara,
Italy, with a Yanagimoto MT-5 CHN recorder elemental analyzer. All tested compounds
yielded data consistent with a purity of at least 95% as compared with the theoretical values.
Optical rotations were assessed at 10 mg/mL in methanol with a Perkin Elmer 241 polarimeter
in a 10 cm water-jacketed cell at 25°C. Reaction courses and product mixtures were routinely
monitored by TLC on silica gel (precoated F254 Merck plates), and compounds were visualized
using an UV lamp. Reagents and solvents were purchased from the Sigma Chemical Co
(St. Louis, MO, USA).
(R) or (S) 2-(4-Isobutylphenyl)-N-(3-methylpyridin-2-yl)propanamide (Ibu-AM5). The
respective (R)(-)-ibuprofen or (S)(+)-ibuprofen (0.21 g, 1 mmol), EDC (0.21 g, 1.1 mmol), and
HOBt (0.13 g, 1 mmol) in dry acetonitrile (10 mL) was stirred at room temperature for 30 min
and then treated with 2-amino-3-methylpyridine (0.11 g, 1 mmol). The mixture was stirred at
room temperature for additional 48 h. Then the solution was evaporated to dryness in vacuo.
The residue was taken up with brine (15 mL) and extracted with AcOEt (2 x 10 mL). The
organic layer was washed sequentially with 10% aqueous sodium carbonate (2 x 5 mL), 10%
aqueous citric acid (2 x 5 mL) and water (2 x 5 mL). The organic layer was dried over anhy-
drous magnesium sulphate, filtered and concentrated to dryness under reduced pressure. The
respective (R)(+)-Ibu-AM5 or (S)(-)-Ibu-AM5 was obtained (58 and 57% yield respectively) in
analytically pure form. 1H NMR (CDCl3): δ 0.86 (d, J = 6.5Hz, 6H, CH3), 1.47 (d, J = 7.0 Hz,
3H, CH3), 1.83 (hept, J = 6.5 Hz, 1H, CH), 2.03 (s, 3H, CH3), 2.41 (d, J = 7.0 Hz, 2H, CH2),
3.88 (q, J = 7.0 Hz, 1H, CH), 6.15 (s, 1H, NH), 6.70 (m, 1H, Py), 7.22 (d, J = 8.0 Hz, 2H, Ar),
7.26 (d, J = 8.0 Hz, 2H, Ar), 7.35 (m, 1H, Py), 7.90 (m, 1H, Py). NMR spectra agree with litera-
ture report for the racemate [23]. IR (nujol) 3297, 3253, 3087, 3050, 1672, 1620, 1579 cm-1.
Optical rotation [α] = -60.9° for (R)(-)-Ibu-AM5 and [α] = +60.8° for (S)(+)-Ibu-AM5.m/z
297 (M + H)+ Anal. Calcd. for C19H24N2O: C, 76.99; H, 8.16; N, 9.45. Found: C, 77.05; H, 8.18;
N, 8.13 for (R)(-)-Ibu-AM5 and C, 76.94; H, 8.19; N, 8.20 for (S)(-)-Ibu-AM5.
2-(4-Isobutylphenyl)-N-(3-methylpyridin-2-yl)acetamide (Ibufenac-AM1). A mixture
of ibufenac (0.19 g, 1 mmol), EDC (0.21 g, 1.1 mmol), and HOBt (0.13 g, 1 mmol) in dry
acetonitrile (10 mL) was stirred at room temperature for 30 min and then treated with
2-amino-3-methylpyridine (0.11 g, 1 mmol). The mixture was stirred at room temperature for
an additional 24 h. Then the solution was evaporated to dryness in vacuo. The residue was
taken up with brine (15 mL) and extracted with AcOEt (2 x 10 mL). The organic layer was
washed sequentially with 10% aqueous sodium carbonate (2 x 5 mL), 10% aqueous citric acid
(2 x 5 mL) and water (2 x 5 mL). Concentration of the dried extracts yielded the title compound
in analytically pure form. Yield 64%; 1H NMR (DMSO-d6) δ 0.86 (d, J = 6.5Hz, 6H, CH3), 1.82
(hept, J = 6.5Hz, 1H, CH), 2.11 (s, 3H, CH3), 2.48 (d, J = 7.0 Hz, 2H, CH2), 3.85 (s, 2H, CH2),
7.08–8.25 (m, 7H, Ar and Py), 10.16 (s, 1H, NH). IR (nujol) 3310, 3270, 3070, 3050, 1668,
1620, 1569 cm-1.m/z 283 (M + H)+ Anal. Calcd. for C18H22N2O: C, 76.56; H, 7.85; N, 9.92.
Found: C, 76.64; H, 7.87; N, 9.87.
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Preparation of rat and mouse brain homogenates
Brains (minus cerebella) from adult Wistar or Sprague-Dawley rats (killed by decapitation)
and from male B6CBAF1/J mice (killed by cervical dislocation), stored at -80°C, were thawed,
weighed and homogenized in cold buffer (20 mMHEPES, 1 mMMgCl2 pH 7.0). Homogenates
were centrifuged (35,000 g at 4°C for 20 min) before the pellet was resuspended in cold homog-
enization buffer. Centrifugation and resuspension was repeated twice. The suspension was
incubated at 37°C for 15 min to degrade any endogenous substrate able to interfere with the
FAAH assay. After centrifugation (35,000 g at 4°C for 20 min), the pellet was resuspended in
cold buffer (50 mM Tris-HCl, 1mM EDTA, 3 mMMgCl2, pH 7.4). The protein concentration
was determined according to [27] after which the samples were frozen in aliquots at -80°C.
Cloning and expression of FAAH wt and FAAH T488A in HeLa cells
The recombinant plasmid (pcDNA4) containing rat Flag-FAAH gene was kindly provided by
Prof. Dale Deutsch (Department of Biochemistry and Cell Biology, Stony Brook University).
The single mutant FAAH (T488A) was obtained using a Quick Change site directed mutagene-
sis kit (Agilent Technologies). The insertion of the corrected mutation was confirmed by DNA
sequencing. The recombinant plasmids pcDNA-FAAHwt and -FAAHT488A were used to trans-
fect HeLa cells by Lipofectamine Ltx (Life Technologies). After 24h of expression, HeLa cells
were detached from the flask with trypsin, washed twice with phosphate buffered saline and
resuspendend in 0.5 mL of the same buffer. Then, the cells were homogenized by means of a
pellet pestle (Sigma). Particulate matter was removed by centrifuging at 3500 g for 20 min. Pro-
tein content was determined by [27] and wt or T488A FAAH expression was visualized by
Western Blot analysis using an anti-FLAG antibody (Sigma Aldrich).
Assay of [3H]AEA hydrolysis in the homogenates and lysates
The assays were performed according to [28] with minor modifications. Briefly, homogenates
or cell lysates in assay buffer (10 mM Tris-HCl, 1mM EDTA, pH 7.4) were mixed with sub-
stance dissolved in ethanol on ice. Hydrolysis reactions were initiated by addition of substrate
([3H]AEA in 10 mM Tris-HCl, 1mM EDTA, pH 7.4 containing 10 mg ml-1 fatty acid-free
bovine serum, assay concentration 0.5 μM unless otherwise stated) and incubation at 37°C. For
the brain homogenates, hydrolysis at 37°C was allowed to proceed for 10 min (assay volume
was 200 μL, with 1 and 0.3 μg/assay protein concentrations of the rat and mouse homogenates,
respectively). For the transfected cells, assay conditions are given in the Figure legend. For the
kinetic experiments, the AEA: fatty acid-free bovine serum albumin ratio was kept constant at
1: ~4.5 (μM). Following incubation, reactions were stopped by addition of 400 μL activated
charcoal (80 μL activated charcoal + 320 μL 0.5 M HCl) and placement of samples on ice before
centrifugation at 2500 rpm for 10 min. Aliquots (200 μL) of the supernatant were analyzed for
tritium content by liquid scintillation spectroscopy with quench correction. Sample sizes were
chosen on the basis of previous data investigating FAAH inhibitory properties of compounds.
Computational studies
Direct interactions between compounds and FAAH were investigated combining molecular
docking studies with molecular dynamics simulations. The simulations were performed with
deprotonated Lys142, as proposed for the catalytic mechanism of FAAH [1]. A preliminary vali-
dation of the computational protocol was performed by reproducing the experimentally deter-
mined binding mode of the pyrrolopyridine inhibitor found in the crystal structure 3QK5,
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which showed the reliability of the procedure not only to reproduce the ligand binding, but
also the position of key water molecules within the active site.
Molecular docking. Rigid docking calculations were performed using the software Auto-
dock 4.2 [29]. The 3D structures of compounds were generated with pymol. Docking was per-
formed on a single monomer of rat FAAH (PDB code: 3QK5 [30], monomer A), after
crystallized ligand removal. Rigid docking was performed using a cubic docking box of 603
grid points, centred on the position of the original ligand (3-{(3R)-1-[4-(1-benzothiophen-
2-yl)pyrimidin-2-yl]piperidin-3-yl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)acetonitrile. The
rotatable bonds of the compounds were detected automatically by Autodock using default
parameters. For each docking run, 100 iterations were performed using default parameters of
Lamarckian genetic algorithm (GALS). The results were clustered on the basis of RMSD crite-
rion ( 4 Å). The representative poses of the best two clusters of each system were used for fur-
ther analysis.
Molecular Dynamics. MD simulations were performed with Amber12 [31] to refine best
docking results. To this end, the representative poses of the best two clusters retrieved from
docking calculations, representing the A- and B- mode for each ligand, were loaded in the two
monomers of the dimeric form of rat FAAH (PDB code: 3QK5,) after removal of the pyrrolo-
pyridine derivative and water molecules. Hence, a total of 8 systems were subjected to molecu-
lar dynamics analysis. A preliminary validation of the computational protocol was obtained by
predicting the experimentally determined binding mode of the pyrrolopyridine derivative in
the 3QK5 crystal structure. The non-covalent ligand of the X-ray structure 3QK5 was chosen
as reference due to the higher structural similarity toward our compounds with respect to car-
profen. It is worth noting that the computational procedure successfully reproduced the bind-
ing mode of the pyrrolopyridine inhibitor, as well as the distribution of water molecules
around the ligand in the binding cavity (see S1 Fig).
Each complex was immersed in a pre-equilibrated octahedral box of TIP3P water molecules,
and the system was neutralized. The final systems contained about 80000 atoms. All simula-
tions were performed with the ff99SBildn force field [32] for the protein and the gaff force field
[33] for the ligands. The charge distribution of the inhibitors was refined using RESP charges
[34] fitted to the B3LYP/6-31G(d) electrostatic potential obtained with Gaussian09 [35]. For
each complex, the geometry was minimized using convergence criterion for the energy gradi-
ent set to 0.01 kcal.(mol.Å)-1 in three steps, which involve: i) hydrogen atoms in the system
(5000 steps of steepest descent and 10000 steps of conjugate gradient), ii) hydrogen atoms,
water molecules and counterions (2000 steps of steepest descent and 18000 steps of conjugate
gradient), iii) finally the whole system (2000 steps of steepest descent and 18000 steps of conju-
gate gradient). Thermalization of the system was performed in four steps of 60 ps, increasing
the temperature from 50 to 298 K. Concomitantly, the atoms that define the protein backbone
were restrained during thermalization using a variable restraining force. Thus, a force constant
of 30 kcal.mol−1.Å−2 was used in the first stage of the thermalization and was subsequently
decreased by increments of 5 kcal. mol−1.Å−2 in the next stages. Then, an additional step of 250
ps was performed in order to equilibrate the system density at constant pressure (1 bar) and
temperature (298 K). Finally, an extended trajectory was run using a time step of 2 fs. SHAKE
was used for those bonds containing hydrogen atoms in conjunction with periodic boundary
conditions at constant pressure and temperature, particle mesh Ewald for the treatment of long
range electrostatic interactions, and a cutoff of 10 Å for non-bonded interactions. The struc-
tural analysis was performed using in-house software and standard codes of Amber 12. All the
systems were subjected to 50 ns of molecular dynamics. One run for (R)-Flu-AM1 and one for
(S)-Ibu-AM5 were extended to 100 ns in order to confirm the structural integrity of the pro-
posed binding mode for the most active enantiomers.
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Homology building. The amino acid sequence of mouse FAAH was retrieved from the
Universal Protein Resource database (http://www.uniprot.org accession ID O08914). The 3D
structure of the target protein was modelled using SWISSMODEL [36]. The X-ray determined
structure of rat FAAH 3QK5 was used as template (covered sequence 100%; sequence identity
of 91.7%).
Statistical analyses
pI50 and IC50 values were calculated using log(inhibitor) vs. response with variable slope (four
parameters) algorithm in the GraphPad Prism computer program (GraphPad Software Inc.,
San Diego, CA. USA). Data was expressed as % of control and the pI50 and IC50 values deter-
mined using uninhibited (top) values set to 100% and minimum (bottom) values either fixed
to zero or allowed to float. The best fit was chosen by Akaike’s informative criteria. Ki and α
values were obtained using the enzyme kinetics mixed model inhibition curve fitting algorithm
available in the GraphPad Prism programme. This models the observed velocity vapp at a given
substrate concentration where vapp = Vmax
app/(1 + Km
app/[S]), Vmax
app = Vmax/(1+[I]/(αKi))
and Km
app = Km(1+[I]/Ki)/(1+[I]/(αKi)) (http://www.graphpad.com/guides/prism/6/curve-
fitting/index.htm?reg_mixered_model.htm, URL checked 16 October 2015). The model
assuming competitive interactions (where α!1) was also used, and the best fit was chosen by
Akaike’s informative criteria. Robust linear regressions for the Dixon plots, which are less sen-
sitive to outliers than the standard least-squares methodology [37] were undertaken using the
same computer programme.
Results
Inhibition of FAAH by the enantiomers of Flu-AM1 and Ibu-AM5
The inhibition of [3H]AEA hydrolysis in rat brain homogenates by the enantiomers of Flu-
AM1 and Ibu-AM5 is shown in Fig 1 and summarised in Table 1. For Flu-AM1, the potencies
of the two enantiomers were very similar, with IC50 values of 0.74 and 0.99 μM being found for
the (R)- and (S)-enantiomers, respectively. In contrast, for Ibu-AM5, the (S)-enantiomer (IC50
value 0.59 μM) was an order of magnitude more potent than the (R)-enantiomer (IC50 value
5.7 μM). Ibufenac-AM1, lacking the methyl group on the C-2 carbon atom and thus lacking
the chiral centre of Ibu-AM5, was a weak inhibitor of rat brain FAAH, with a pI50 value of
4.17±0.04 (IC50 value of 68 μM) as compared with the pI50 value of 5.92±0.09 (IC50 of 1.2 μM)
for racemic Ibu-AM5 (Fig 1F). Time-dependency and reversibility experiments were under-
taken for (R)-Flu-AM1 (Fig 2). There was a small degree of time-dependency for (R)-Flu-AM1,
Table 1. Species-dependent inhibition of FAAH by the enantiomers of Flu-AM1 and Ibu-AM5.
Rat brain Mouse brain
pI50 IC50 (μM) nH pI50 IC50 (μM) nH
(R)-Flu-AM1 6.13±0.03 0.74 0.90±0.04 5.05±0.06* 8.8* 0.78±0.09
(S)-Flu-AM1 6.00±0.02 0.99 0.94±0.04 4.96±0.04* 11* 1.31±0.16
(R)-Ibu-AM5 5.25±0.05# 5.7 1.05±0.10 4.28±0.07 53 1.50±0.36
(S)-Ibu-AM5 6.23±0.06 0.59 0.81±0.08 5.16±0.11 7.0 1.33±0.38
Unless otherwise stated, the IC50 values were calculated using a maximum inhibition of 100%.
#Best ﬁt was for maximum inhibition of 92±4%. Data calculated from 3–6 experiments using a [3H]AEA concentration of 0.5 μM.
*Data from from [26]. nH refers to the Hill slopes returned by the analyses.
doi:10.1371/journal.pone.0142711.t001
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but it was less pronounced than for the irreversible inhibitor URB597. Thus, for example, the
% activity remaining in the presence of 0.7 μM (R)-Flu-AM1 was 50±1% and 39±4% after
Fig 2. Time-dependency and reversibility of the inhibition of rat brain FAAH by (R)-Flu-AM1. Panels A and B show the time-dependencies of (R)-Flu-
AM1 and URB597, respectively. The data are means ± SEM, N = 3. In Panel C, homogenates (at 20-fold normal strength) were preincubated with either
vehicle, 2, 4 or 6 μM (R)-Flu-AM1 for 60 min. Aliquots were then diluted 20-fold and assayed for FAAH activity. These are shown as 2!0.1, 4!0.2 and 6
!0.3. Concomitantly, (R)-Flu-AM1 was added to vehicle-preincubated aliquots to give concentrations of 0.1, 0.2 and 0.3 μM (representing free
concentrations after a 20- fold dilution), 2, 4 and 6 μM final concentrations. The panel shows the data as % of corresponding control (means ± SEM, N = 3).
For a fully reversible compound, the inhibition seen in the yellow bars (i.e. following the dilution) should be lower than in the purple bars (the inhibition seen at
the undiluted concentrations) but equal to the green bars (the free concentrations after the dilution).
doi:10.1371/journal.pone.0142711.g002
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preincubation for 0 and 60 min at 37°C, respectively. The corresponding values for 30 nM
URB597 were 52±1% and 19±3%, respectively. Further, dilution experiments conducted after
60 min of preincubation indicated that the inhibition produced by (R)-Flu-AM1 was
completely reversible in nature (Fig 2).
The ability of the enantiomers of Ibu-AM5 to inhibit FAAH was also investigated in mouse
brain homogenates (Table 1). The pattern of enantiomeric selectivity for Ibu-AM5 was also
seen in the mouse brain homogenates. However, the potencies of the enantiomers of Ibu-AM5
were about an order of magnitude lower in the mouse brain homogenates compared with the
rat brain homogenates, and the same is true for the enantiomers of Flu-AM1. To aid the reader,
the pI50 and hence IC50 values obtained in [26] for inhibition of mouse brain FAAH by the
Flu-AM1 enantiomers are given in Table 1.
Mode of inhibition of rat brain FAAH by (R)- and (S)-enantiomers of Flu-AM1 and
Ibu-AM5. The inhibition of the hydrolysis of 0.5–4 μM of added [3H]AEA by the (R)- and
(S)-enantiomers of Flu-AM1 are shown in Fig 3. The data for the untransformed curves (left
panels for the figures) were in both cases better fitted to a model assuming a linear mixed inhi-
bition (see Statistics section of Materials and Methods for a description of the model) than a
model assuming a pure competitive interaction. For (R)-Flu-AM1, the model returned Ki and
α values of 0.63±0.17 μM and 3.2±1.3, respectively (Fig 3A, left panel). For (S)-Flu-AM1, the
corresponding values were 0.79±0.28 μM and 5.6±3.6, respectively (Fig 3B, left panel). Dixon
plots were also constructed for the data (Fig 3A and 3B right panels). For a mixed-type inhibi-
tor, the straight lines obtained at each substrate concentration should intersect at a value
which, when projected onto the x-axis, corresponds to -Ki [38,39]. For eight substrate concen-
trations as here, there are 28 different intersections. In an analogous situation, the direct linear
Fig 3. Kinetics of inhibition of FAAH by A, (R)-Flu-AM1; B, (S)-Flu-AM1; C, (R)-Ibu-AM5 and D, (S)-Ibu-AM5. Left panels shown are means ± SEM,
N = 3–4, when not enclosed within the symbol, of the FAAH activity at the added concentrations shown of AEA. Right panels show Dixon plots of the mean
data. The dotted lines show the projections of the median intersection point on the axes.
doi:10.1371/journal.pone.0142711.g003
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plot of Eisenthal and Cornish-Bowden [40], those authors used the median values to solve the
issue of undue influence of outliers on intersections. Using this approach, Ki values for (R)-
and (S)-Flu-AM1 of 0.28 and 0.86 μM, respectively, were found.
The two enantiomers of Ibu-AM5 were also investigated, and again, both datasets were bet-
ter fitted by the linear mixed inhibition model than by a pure competitive inhibition model.
(S)-Ibu-AM5 inhibited rat brain [3H]AEA hydrolysis with Ki and α values of 0.80±0.21 μM
and 3.2±1.5, respectively, and the Dixon plot gave a Ki value of 0.89 μM (Fig 3C). The corre-
sponding values for the (R)-enantiomer were 10±2.5 μM and 3.1±1.1, respectively; Dixon plot
Ki value 9.8 μM (Fig 3D).
Multiple inhibition experiments. Experiments where two inhibitors are investigated
together are a useful way of determining whether the compounds act in a mutually exclusive
manner or in a cooperative manner [39]. In essence, the activity of the enzyme in the presence
of different concentrations of both compounds is assessed and the data plotted as 1/v vs. the
concentration of one of the compounds, i.e. a Dixon plot. For two compounds acting in a
mutually exclusive manner, the Dixon plots should show a series of parallel lines, whereas for
two compounds interacting in a co-operative manner, the lines should form a “V”-shape
towards the y axis [39]. We investigated the interaction between either (R)-Flu-AM1 or (S)-
Ibu-AM5 and carprofen (Fig 4). When analysing the data for carprofen per se, we noted that
the Hill slope, nH was greater than expected (see S1 Appendix). However, this can satisfactorily
be explained in terms of its interaction with the fatty acid-free bovine serum albumin in the
assay, whereby the free carprofen concentration available for interaction with FAAH is not
directly proportional to the added concentration (for analysis see S1 Appendix). Given the
uncertainty concerning the free carprofen concentrations, we have presented the data showing
the -AM compound concentrations on the x-axes and with the different lines corresponding to
each added carprofen concentration (Fig 4). In this way, parallel lines vs. a “V”-shape can be
identified without making assumptions about the free carprofen concentrations. There was no
obvious evidence of a “V”-shape in the Dixon plots, suggesting that the inhibitors act upon
FAAH in a mutually exclusive manner.
Inhibition of wild-type FAAH and FAAHT488A by (R)-Flu-AM1 and carprofen
The simplest explanation for the mutual exclusivity of the -AM compounds and carprofen
described above is that they share a binding site on the FAAHmolecule. Given the report by
Bertolacci et al. [11] that the potency of carprofen was lower towards FAAHT488A than wild-
type FAAH, consistent with their model of carprofen interaction with the enzyme, we investi-
gated (R)-Flu-AM1 and carprofen in HeLa cells transfected with the two recombinant FAAH
proteins.
Initial time courses indicated that the catalytic activity of the FAAHT488A lysates was very
low. In consequence, a long incubation time (18 h at 37°C) was necessary. Under these condi-
tions, (R)-Flu-AM1 indeed inhibited AEA hydrolysis by lysates expressing wild-type FAAH
more potently than by lysates expressing FAAHT488A (Fig 5A). In order to check that this dif-
ference was not a reflection of the different assay protein contents (lower for the wild type
FAAH lysates than for the FAAHT488A lysates in view of their different catalytic activities), the
inhibition of a mixture of wild-type lysates and lysates containing the empty vector (which
lacked overt AEA-hydrolytic activity) were combined to give the same protein concentration
as the FAAHT488A lysates. Addition of the lysates containing the empty vector did not affect
the observed potency of (R)-Flu-AM1 towards wild-type FAAH (Fig 5A). Carprofen was also
less potent in the FAAHT488A lysates than the wild-type FAAH lysates (Fig 5B), but the steep
inhibition curves for the samples will tend to minimise changes in potency, assuming that the
high nH values reflect saturation with fatty acid-free bovine serum albumin as a limiting factor
(S1 Appendix). As for (R)-Flu-AM1, addition of the lysates containing the empty vector did
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not affect the observed potency of carprofen towards wild-type FAAH (Fig 5B). It was noted
that the potency of (R)-Flu-AM1 towards wild type FAAH was lower than seen in the rat brain
homogenates, but it is hard to compare these values given that the experimental conditions are
so different. Indeed, in preliminary experiments using another batch of wild-type FAAH, 1.5–
2 μg/assay and incubation times of 20 min at 37°C, the potencies of (R)- and (S)-Flu-AM1 (1.6
and 2.4 μM, respectively) and (R)- and (S)-Ibu-AM5 (8.8 and 0.53 μM, respectively, data from
two experiments) were reasonably similar to the rat brain FAAH values.
Fig 4. Multiple-inhibitor experiments for the inhibition of rat brain [3H]AEA (0.5 μM) hydrolysis using carprofen and either A, B, (R)-Flu-AM1, or C,
D, (S)-Ibu-AM5. The left panels show the untransformed data and are means ± SEM, N = 3–4. The right panels show the Dixon plots of the mean data.
doi:10.1371/journal.pone.0142711.g004
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Molecular dynamics studies
The binding modes of the enantiomeric forms of Flu-AM1 and Ibu-AM5 to the rat FAAH
enzyme were studied by combining docking studies and MD simulations using a protocol
which was successful in predicting the binding mode of non-covalent ligands (see Materials
and Methods section). The docking results were ranked considering the cluster population and
the binding energy. The results showed that the ligands bind to a region formed by the acyl
chain binding (ACB) channel and the membrane access channel (MAC), filling the cavity
experimentally found for other non-covalent ligands [10,11]. Two binding modes that differ in
the orientation of the amide moiety were found. Thus, the amide moiety points toward either
the catalytic triad (A-mode) or the membrane interacting helices α18-α19 (B-mode). The B-
mode was found to be the most populated cluster for the two enantiomers, but the scores of
A- and B-modes were highly similar, thus preventing a firm distinction between the ligand ori-
entations (S1 Table).
To check the structural integrity of two binding modes, the best poses of each docking clus-
ter were submitted to 50 ns of all atomMD simulation. As a general trend, the simulations
starting from the B-mode remained stable along the whole trajectory, whilst the ligand showed
significant rearrangements when the simulation started from the A-mode. As an example, this
is reflected in the positional root-mean square-deviation (RMSD) profiles obtained for (R)-
and (S)-Flu-AM1, which show much larger fluctuations in the A-mode binding (S2 Fig). More-
over, the B-mode binding generally led to a consistent pattern of interactions in the binding
pocket, whereas the A-mode exhibited less consensus in the interactions between ligand and
protein. As an additional test, an independent MD simulation was run for (R)-Flu-AM1 bound
to FAAH dimer starting from the B-mode binding, and the results confirmed the structural
integrity of the ligand arrangement (see below). Therefore, in the following the discussion is
limited to the structural features of the B-mode simulations.
Fig 5. Inhibition of rat wild-type and FAAHT488A by A. (R)-Flu-AM1 and B. carprofen. Samples were incubated for 18 h with inhibitor and substrate
(0.5 μM [3H]AEA). The concentrations of lysates used were FAAHwt, 0.04 μg/assay, FAAHT488A, 0.4 μg/assay, empty vector 0.36 μg/assay. Shown are
means ± SEM, N = 3–6. The pI50 values, with corresponding IC50 and nH values in brackets were: (R)-Flu-AM1: FAAH
wt, 5.08±0.03 (8.3 μM; nH = 1.02±0.07);
FAAHT488A, 4.55±0.07 (28 μM; nH = 1.47±0.37), FAAH
wt + empty vector, 5.10±0.02 (8.0 μM; nH = 0.99±0.06). Carprofen: FAAH
wt, 4.43±0.02 (37 μM, nH =
3.00±0.31); FAAHT488A, 4.32±0.04 (48 μM, nH = 2.43±0.37), FAAH
wt + empty vector, 4.50±0.01 (32 μM; nH = 4.28±0.41. Note that for carprofen and wild-type
FAAH, the analyses suggested that a curve with a maximum inhibition of 82–91% fitted the data better than a curve with 100%maximum inhibition, and these
values have been used here.
doi:10.1371/journal.pone.0142711.g005
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Three out of the four ligand-bound systems run for (R)-Flu-AM1 converged to a common
binding mode, which is characterized by a stable hydrogen bond between the hydroxyl group
of Thr488 and the carbonyl unit of (R)-Flu-AM1 (Fig 6A), as noted in the similar arrangement
obtained upon superposition of representative snapshots (see S3 Fig). The ligand is closely
packed in the binding site, forming interactions that are preserved along most of the trajectory
(Fig 6A). The biphenyl moiety fills a hydrophobic cavity, with the distal ring pointing to the
centre of the anionic hole and forming van der Waals contacts with hydrophobic residues lin-
ing the ACB channel (Ile491, Phe381, Leu380, Ile238 and Phe194). No specific interactions were
observed for the methyl group on the chiral centre. On the other side, transient hydrogen
bonds were observed between the pyridine nitrogen and either the backbone of Asp403 or alter-
natively Gly485 (through a water molecule), and between the amide NH unit and the backbone
of Leu401 (S3 Fig). Van der Waals contacts are also formed with Met436 and Ile407. The struc-
tural integrity of this binding mode was maintained upon extension of the trajectory up to 100
ns (data not shown).
The MD trajectories run for (S)-Flu-AM1 led to similar ligand poses in the two monomers
of FAAH. The results showed that the amide bond establishes stable hydrogen bonds between
the amide NH unit and the backbone of Gly485, and between the amide carbonyl with the
Thr488 side chain (Fig 6B). Moreover, the biphenyl system formed van der Waals contacts with
hydrophobic residues in the ACB channel (Leu192, Ile491, Phe381, Leu401, Phe432). The methyl
group on the chiral carbon pointed toward Leu404 and Leu401.
Comparison of (R)- and (S)-Flu-AM1 binding modes is shown in Fig 6, which highlights
how the enantiomers were bound in slightly different arrangements in the same site located
between ACB and the MAC channels. Nevertheless, the enantiomers showed a very similar
pattern of interactions: i) the aromatic rings formed a number of van der Waals contacts
mainly involving aliphatic side chains, ii) the fluorine atom weakly interacted with Phe381, and
iii) the amidopyridine moiety established hydrogen-bonds with Gly485 and Thr488.
MD simulations of (S)-Ibu-AM5 B-mode converged to similar binding modes in the two
monomers of FAAH. Extension of the MD simulation to 100 ns confirmed the stability of the
B-mode, which remained stable for the last 70 ns of the simulation. (S)-Ibu-AM5 binds at the
bottom of the ACB channel and the MAC (Fig 7A) with the pyridine nitrogen fitting the posi-
tion of the carprofen carboxylic group (PDB code 4DO3) (S4 Fig). The pyridine ring is firmly
packed in a hydrophobic cavity in the proximity of the membrane, interacting with hydropho-
bic residues at the gorge of the MAC (Trp531, Leu429 and Ile407). The amide unit of the ligand
formed hydrogen-bonds with the backbone carbonyl of Gly485 and to the Thr488 side chain
(Fig 7A). The profen moiety is placed in the apolar gorge of the ACB with the methyl group on
the chiral carbon pointing toward Leu404 and Leu401.
Simulations run for (R)-Ibu-AM5 also supported the B-mode binding, leading to similar
ligand arrangements in the two monomers. Compared to the (S)-enantiomer, most of the dif-
ferences arise from the pattern of interactions established by the amidopyridine moiety, since a
hydrogen bond was formed between the carbonyl unit of the amide group and the hydroxyl
group of Thr488 and the pyridine nitrogen formed a water-mediated contact with Gly485
(Fig 7B), in addition to hydrophobic contacts with Trp531, Ile407 and Phe381.
Discussion
In the present study, the interaction of the enantiomers of Flu-AM1 and Ibu-AM5 with rat
FAAH have been extensively studied in order to determine the importance of the presence of
the chiral centre and its configuration. (R)-Flu-AM1 was marginally more potent than the cor-
responding (S)-enantiomer as an inhibitor of FAAH, a result also seen for flurbiprofen [17]. In
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Fig 6. Representation of (R)-Flu-AM1 (A) and (S)-Flu-AM1 (B) in the competitive binding site of the
dimeric FAAH as obtained fromMD simulations.
doi:10.1371/journal.pone.0142711.g006
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Fig 7. Representation of (S)-Ibu-AM5 (A) and (R)- Ibu-AM5 (B) in the competitive binding site of the
dimeric FAAH as obtained fromMD simulations.
doi:10.1371/journal.pone.0142711.g007
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contrast, the (R)-enantiomer of Ibu-AM5 was 10-fold less potent an inhibitor of FAAH than
the (S)-enantiomer, in direct contrast to ibuprofen, where the (R)-enantiomer is more potent
than the (S)-enantiomer [17]. Interestingly, the presence of the methyl at the C-2 carbon atom
of Ibu-AM5 is more important than its configuration for FAAH inhibitory activity, since ibufe-
nac-AM1 was less potent an inhibitor of FAAH than Ibu-AM5.
The computational studies suggested that Flu-AM1 and Ibu-AM5 bind a region located
between the ACB channel and the entrance of the MAC, filling the binding site of other non-
covalent inhibitors, such as carprofen [11] (PDB code 4DO3) and the pyrrolopyridine inhibitor
in the 3QK5 crystal structure (S4 Fig). Among the two possible binding modes found in dock-
ing studies, MD simulations showed that only the B-mode forms a relevant interaction with
Thr488. This conclusion was supported by the finding that (R)-Flu-AM1 is a less potent inhibi-
tor of the FAAHT488A mutant enzyme than of the wild-type enzyme. The data with the wild
type and FAAHT488A mutant with carprofen are consistent with those of [11], although they
found a larger shift despite a lower assay albumin concentration, and lend support to their
model that carprofen interacts with Thr488 at the entrance to the substrate binding pocket for
rat FAAH. On the other hand, the proposed binding mode differs from the one proposed for a
series of 1,3,4-oxadiazol-2-ones derivatives of ibuprofen and flurbiprofen [13]. A reasonable
explanation of differences in the binding mode can be found in the higher polarity of the
1,3,4-oxadiazol-2-one moiety compared to the pyridine unit, which would make the coordina-
tion with the oxyanion hole the main driving force upon binding.
The comparison of the best representative poses of (R)- and (S)-Flu-AM1 showed very dif-
ferent binding modes for the two enantiomers, with the (S)-enantiomer binding deeper in the
MAC. The same behaviour was observed from the MD simulations of (R)- and (S)-Ibu-AM5
(S5 Fig) suggesting that chirality is a main determinant of the binding mode. Interestingly, this
behaviour seems to be associated to the conformational change of Phe432. In the MD trajecto-
ries of (S)-enantiomers the Phe432 χ1 dihedral switched from 90° to 180°, allowing the packing
of the methylpyridine ring in a hydrophobic cavity formed by Trp531, Leu429 and Ile407 (S2
Table). The same Phe432 rotamer (χ1 = 180°) was found in the crystal structure of the rat FAAH
in complex with an anandamide analogue (PDB code 1MT5). In contrast, in the binding of the
(R)-enantiomers, Phe432 assumes the same conformation found in 3QK5 and 4DO3 crystal
structures (χ1 = 90°).
The enzymatic assays showed that these differences in the binding mode slightly affected
the activity of Flu-AM1 enantiomers, while it has more remarkable effect on the Ibu-AM5
enantiomers. The binding modes of (R)- and (S)-Flu-AM1 were characterized by a similar pat-
tern of hydrophobic interactions and two hydrogen bonds that is in full agreement with the
similar activities showed by these enantiomers. On the contrary, the (S)-Ibu-AM5 binding
mode was more stable in the light of the higher member of H-bonds.
The above discussion has only considered a single binding site for the compounds. How-
ever, the kinetic experiments suggested a mixed type of inhibition, with a value of α in single
figures. A mixed-type inhibition has often been suggested to imply an allosteric mode of inhibi-
tion, but this is not necessarily so, and there are many examples of compounds that produce
kinetics that are not competitive despite their binding to the active site [41]. One possible
mechanism, seen with some NSAIDs such as flurbiprofen (but not ibuprofen) and their inter-
actions with COX, is a two-step reaction whereby an initial competitive interaction is followed
by a slower tight-binding or even irreversible inhibition. However, in these cases, the time-
dependency is very marked, occurring over minutes [42]. In the present case, there was some
apparent time-dependency with (R)-Flu-AM1, but it was very slow, and we have previously
not seen such time-dependency with racemic Flu-AM1, despite its mixed-type mode of inhibi-
tion [22]. We thus do not favour this mechanism as an explanation for our data. A simpler
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mechanism for a fully reversible linear-mixed type inhibitor is for the compound to bind to
two mutually exclusive sites [39]. Such a model would be consistent with the data, since all that
is required in the multiple inhibition experiments with carprofen is mutual exclusivity rather
than a specific locus of action [39].
We noted a difference in potencies between inhibition of rat and mouse FAAH by the enan-
tiomers of Flu-AM1 and Ibu-AM5. Pronounced species-dependency has also been reported for
carbamate and urea FAAH inhibitors [7,43], although these studies did not compare rat with
mouse FAAH. Interestingly, the inhibition of mouse brain FAAH by (R)-Flu-AM1 is competi-
tive rather than mixed [26]. In theory, differences in the amino acid compositions in the bind-
ing site of rat and mouse FAAHmay account for the potency differences of the enantiomers in
the two species. The alignment of the mouse and rat FAAH structures revealed only two differ-
ences within the (R)-FluAM1 binding site, Phe194 to Tyr and Ile407 to Val. We built a 3D model
of the mouse FAAH to evaluate the effects of these mutations on the binding site. These muta-
tions did not change the binding site shape, as shown in S6 Fig, and therefore they should not
affect to a dramatic extent the inhibitory potency of (R)-FluAM1. This may mean that there is
a species difference in the structure of the enzyme at this additional site. Further experiments
are required to be able to identify the site on the enzyme.
Conclusions
The present study has used a range of biochemical, pharmacological, molecular biological and
computational methods to explore the interaction of the enantiomers of Flu-AM1 and Ibu-
AM5 with FAAH. Given the potentially useful properties of compounds with combined
FAAH–COX inhibitory properties [25,44], the characterisation of the binding of the com-
pounds to the substrate access channel of FAAH may provide vital information for the optimi-
sation of such compounds.
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S5 Fig. Superimposition of the binding mode proposed for (S)-enantiomers (A) and (R)-
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S6 Fig. Superimposition of the model of mouse FAAH (green) to the binding mode of (R)-
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